On the Record · Jazz Pharmaceuticals
Jazz Pharmaceuticals competitors, on the record
The companies Jazz Pharmaceuticals names as competitors in its annual reports, 2023 to 2025, and the companies that name Jazz Pharmaceuticals, each with the sentence and the filing.
Who Jazz Pharmaceuticals names
| Company | Named in |
|---|---|
| Alkermes | 2025 |
| Amgen Inc. | 2025 |
| Axsome | 2025 |
| Harmony Biosciences | 2025 |
| Hikma | 2025 |
| Stoke Therapeutics, Inc. | 2025 |
In its own words
Alkermes
Word for word“Xywav and Xyrem face competition from Alkermes’ Lumryz (acquired through its acquisition of Avadel), a branded product for treatment of cataplexy and/or EDS in narcolepsy.” 10-K for 2025
Amgen Inc.
Word for word“There are also a number of products for the treatment of first and second line SCLC in various phases of development, including Amgen Inc.’s tarlatamab, which was approved for second line use in the U.S. in May 2024.” 10-K for 2025
Axsome
Word for word“Other companies have announced that they have product candidates in various phases of development to treat the symptoms of narcolepsy, such as Axsome’s reboxetine, and various companies are performing R&D on orexin 2 receptor agonists for the treatment of sleep disorders, including narcolepsy and IH, which companies include Takeda, Merck & Co., Inc., Eisai Co., Ltd., Centessa Pharmaceuticals plc and Alkermes.” 10-K for 2025
Harmony Biosciences
Word for word“Harmony Biosciences has announced a phase 3 study for pitolisant for IH after receiving a refusal to file from FDA in February 2025.” 10-K for 2025
Hikma
Word for word“Pursuant to our patent litigation settlement with the first filer, Hikma launched its AG version of high-sodium oxybate in the U.S. beginning on January 1, 2023.” 10-K for 2025
Stoke Therapeutics, Inc.
Word for word“There are a number of public and private companies in various stages of developing genetic therapies for DS, including Stoke Therapeutics, Inc., which has an antisense oligonucleotide, STK-001, in clinical trials.” 10-K for 2025
Who names Jazz Pharmaceuticals
Companies whose own annual reports name Jazz Pharmaceuticals as a competitor.
Word for word“Our principal competitors in the specialty pharmaceutical market include Supernus Pharmaceuticals, Inc., Jazz Pharmaceuticals PLC, AbbVie Inc., and Alkermes PLC.” 10-K for 2025
Word for word“This segment’s major competitors, including Viatris Inc. (Viatris), Jazz Pharmaceuticals plc (Jazz), Takeda Pharmaceutical Company Limited and Amgen, Inc., among others, vary depending on therapeutic and product category, dosage strength and drug-delivery systems, among other factors.” 10-K for 2024
Word for word“This segment’s major competitors, including Viatris Inc. (Viatris), Jazz Pharmaceuticals plc (Jazz), Takeda Pharmaceutical Company Limited and Amgen, Inc., among others, vary depending on therapeutic and product category, dosage strength and drug-delivery systems, among other factors.” 10-K for 2023
Read from Jazz Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.